Any current/future new fundraising through debt or equity?

The company prepaid around INR804 crores in the recent quarter, partly funded by INR467 crores through an equity issue in November 2025 and the rest from cash flow. There is a liability of INR268 crores due in FY '26-'27, planned to be paid off. The company is in the process of reducing debt further and targeting prepayments based on cash flow but has not committed to a fixed repayment amount. Plans for raising capital through debt or equity beyond this are not explicitly mentioned, indicating no immediate new fundraising is announced. Management aims to achieve a debt-free status for

Any current/future capex/capital investment/strategic investment?

INR 830 crores capital expenditure done in the year, with about INR 400 crores invested in two main grain distilleries located at Gorakhpur and Kashipur. Additional smaller capex projects completed besides the distilleries. Future debt repayments planned: INR 268 crores liability for FY27, with ongoing efforts to reduce debt further based on cash flow. Scheme of arrangement for demerger expected to have NCLT hearing by May 21, 2026, with anticipated order in early June, paving way for restructuring and potential strategic moves thereafter. Continued investments in Ennature Biopharma se

Future growth expectations in sales/revenue/volumes?

Chemicals segment expected to see good growth driven by performance chemicals and new products like bio-based amines and dibasic esters. Potable Spirits revenue growing, driven by premiumization in IMFL and new product launches (e.g., Bunty Vodka 122% growth, Bunty Jamun). Bio-Fuels segment shows strong growth with 40.9% increase in FY26 revenue; potential for further growth if ethanol blending targets rise beyond 20% and flexi-fuel vehicles expand. Ennature Biopharma targeting volume growth via new customer additions, clinical-backed nutraceutical launches, and planned entry into the U.

Future growth expectations in earnings/operating earnings/profits/EPS?

Chemicals business: Cautiously optimistic with expected improved profitability and top-line growth; performance chemicals segment growing strongly with potential for doubling revenue this year and sustained momentum. Bio-Fuels: Strong growth driven by 20% ethanol blending policy, with possible future increases beyond 20%; profitability expected to remain healthy due to stable grain prices and policy support. Ennature Biopharma: Profitability under pressure but expected to improve due to diversification into branded nutraceuticals, clinical studies, and expansion into US markets. Potable Spirit

IN US

Sale is live|00:00:00left today

India Glycols LtdQ1 FY26Beverages

India Glycols Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹944P/E: 23.3Market Cap: ₹6.8K CrSector: Beverages

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Chemicals segment expected to see good growth driven by performance chemicals and new products like bio-based amines and dibasic esters.
→Potable Spirits revenue growing, driven by premiumization in IMFL and new product launches (e.g., Bunty Vodka 122% growth, Bunty Jamun).
→Bio-Fuels segment shows strong growth with 40.9% increase in FY26 revenue; potential for further growth if ethanol blending targets rise beyond 20% and flexi-fuel vehicles expand.
→Ennature Biopharma targeting volume growth via new customer additions, clinical-backed nutraceutical launches, and planned entry into the U.S. market.
→Capex focused on expanding two grain distilleries (Gorakhpur and Kashipur) supports future production capacity.
→Ongoing efforts to improve Chemicals business quality and expand product portfolio expected to sustain growth.
→Premiumization strategy in Potable Spirits likely to increase revenue share from IMFL and improve margins.
→Bio-Fuels expected to benefit from government policy support and stable input costs, supporting volume and profit growth.

Margin guidance

Category 3

→Chemicals business: Cautiously optimistic with expected improved profitability and top-line growth; performance chemicals segment growing strongly with potential for doubling revenue this year and sustained momentum.
→Bio-Fuels: Strong growth driven by 20% ethanol blending policy, with possible future increases beyond 20%; profitability expected to remain healthy due to stable grain prices and policy support.
→Ennature Biopharma: Profitability under pressure but expected to improve due to diversification into branded nutraceuticals, clinical studies, and expansion into US markets.
→Potable Spirits: Margins maintained around 22%; growth driven by premiumization and new product launches in key regions.
→Overall EBITDA margin improved to 15.5% in FY26, with 24.5% EBITDA growth and 26.8% PAT growth, indicating strong earnings momentum going forward.
→Debt reduction and cost control measures leading to better interest coverage and financial health, supporting future profit growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company prepaid around INR804 crores in the recent quarter, partly funded by INR467 crores through an equity issue in November 2025 and the rest from cash flow.
→There is a liability of INR268 crores due in FY '26-'27, planned to be paid off.
→The company is in the process of reducing debt further and targeting prepayments based on cash flow but has not committed to a fixed repayment amount.
→Plans for raising capital through debt or equity beyond this are not explicitly mentioned, indicating no immediate new fundraising is announced.
→Management aims to achieve a debt-free status for the Chemical business by FY '28-'29 using proceeds from partial equity sale of the JV.
→Interest costs are expected to remain at around INR25 crores per quarter, suggesting stable financing costs without significant new borrowings.

Order book

The transcript provided from India Glycols Limited's Q4 & FY26 earnings call does not specifically mention details about the current or expected order book or pending orders. Key focuses instead were on: - Capital expenditure mainly in two grain distilleries (Gorakhpur and Kashipur). - Debt repayment and reduction plans. - Business segment performances including Chemicals, Potable Spirits, Bio-Fuels, and Ennature Biopharma. - Shifts towards premiumization in the Potable Spirits segment. - Updates on JV performance and monetization timelines. - Impact of plant shutdowns on production and sales. Therefore, there is no explicit information available about the current or expected order book or pending orders in this document.

Capex plans

Yes

→INR 830 crores capital expenditure done in the year, with about INR 400 crores invested in two main grain distilleries located at Gorakhpur and Kashipur.
→Additional smaller capex projects completed besides the distilleries.
→Future debt repayments planned: INR 268 crores liability for FY27, with ongoing efforts to reduce debt further based on cash flow.
→Scheme of arrangement for demerger expected to have NCLT hearing by May 21, 2026, with anticipated order in early June, paving way for restructuring and potential strategic moves thereafter.
→Continued investments in Ennature Biopharma segment focusing on manufacturing capabilities and customer acquisition for growth and profitability enhancement.
→Ongoing strategic shift towards premiumization in Potable Spirit segment with focus on launching more premium brands for future revenue increase.

How does India Glycols Ltd rank vs peers in Beverages?

Pro feature

1India Glycols Ltd

Rev 3Mar 3

See full Beverages sector rankings

Want more stocks like India Glycols Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio